US 12,234,285 B2
Antibodies that bind interleukin-2 and uses thereof
Marina Roell, Berkeley, CA (US); Mark Rubinstein, Charleston, SC (US); Hassan Issafras, Emeryville, CA (US); Llewelyn Lao, San Francisco, CA (US); Ou Li, Dublin, CA (US); Daniel H. Bedinger, Pleasant Hill, CA (US); Kristin Camfield Lind, Oakland, CA (US); Agnes Choppin Holmes, Mountain View, CA (US); Toshihiko Takeuchi, Oakland, CA (US); Lauren Schwimmer, Alameda, CA (US); Hoa Giang, Alameda, CA (US); Amer M. Mirza, San Francisco, CA (US); and Kirk W. Johnson, Moraga, CA (US)
Assigned to XOMA (US) LLC, Emeryville, CA (US); and MUSC FOUNDATION FOR RESEARCH DEVELOPMENT, Charleston, SC (US)
Filed by XOMA (US) LLC, Emeryville, CA (US); and MUSC FOUNDATION FOR RESEARCH DEVELOPMENT, Charleston, SC (US)
Filed on Dec. 4, 2020, as Appl. No. 17/112,664.
Application 17/112,664 is a division of application No. 15/718,152, filed on Sep. 28, 2017, granted, now 10,858,428.
Claims priority of provisional application 62/421,038, filed on Nov. 11, 2016.
Claims priority of provisional application 62/401,158, filed on Sep. 28, 2016.
Prior Publication US 2021/0188969 A1, Jun. 24, 2021
Int. Cl. C07K 16/24 (2006.01); A61K 38/20 (2006.01); A61K 39/395 (2006.01); A61P 11/06 (2006.01); A61P 31/04 (2006.01); A61P 35/00 (2006.01); A61P 37/06 (2006.01); C07K 16/18 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01); C07K 14/55 (2006.01)
CPC C07K 16/246 (2013.01) [A61K 38/2013 (2013.01); A61K 39/395 (2013.01); A61K 39/3955 (2013.01); A61P 11/06 (2018.01); A61P 31/04 (2018.01); A61P 35/00 (2018.01); A61P 37/06 (2018.01); C07K 16/18 (2013.01); C07K 16/28 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/24 (2013.01); C07K 2317/32 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 14 Claims
 
1. A method for treating a disease, condition or disorder associated with increased interleukin-2 (IL-2) or interleukin-2 receptor (IL-2 R) levels or activity comprising the step of administering to a subject in need thereof a therapeutically effective amount of a human or humanized antibody that binds human interleukin-2 (IL-2) with an affinity KD of 1×10−10 M or less and inhibits binding of IL-2 with an IL-2 receptor alpha (IL-2 Rα) subunit,
wherein the antibody inhibits IL-2 signaling through IL-2 Rαβγ and through IL-2 Rβγ, and
wherein the antibody inhibits IL-2 signaling through IL-2 Rαβγ to a greater extent than through IL-2 Rβγ,
wherein the disease, condition or disorder is cancer, and
wherein the antibody is administered in combination with IL-2 or an IL-2 variant.